

NICKEL ET AL. -- 10/686,809  
Client/Matter: 051744-0306034

REMARKS

The examiner has determined that claim 14 is generic to a plurality of disclosed species. The examiner states that Applicants are required to elect a single disclosed species from those disclosed in the specification or in claim 26, and that Applicants are further required to elect an antitumor agent from those recited in claims 25 and 26. Because claims 25 and 26 list four antitumor agents, Applicants understand that a complete reply to this Restriction Requirement involves the election of one of the four antitumor agents recited in claims 25 and 26. Accordingly, Applicants elect doxorubicine as the antitumor agent. This election is readable on pending claims 14-29.

The Commission for Parents is authorized to charge any fees associated with this submission to Deposit Account No. 033975.

Respectfully submitted,

Pillsbury Winthrop Shaw Pittman LLP

Date: April 10, 2006

By: 

Jeffrey N. Townes

Registration No.: 47,142

Pillsbury Winthrop Shaw Pittman, LLP  
1650 Tysons Blvd.  
McLean, VA 22102  
General Telephone No.: 703.770.7900  
General Facsimile No.: 703.770.7901